SGLT-2 Inhibition: Novel therapeutics for reno-and cardioprotection in diabetes mellitus

Research output: Contribution to journalReview ArticleResearchpeer-review

2 Citations (Scopus)

Abstract

Background: The sodium glucose co-transporter 2 (SGLT2) is primarily located within S1 of the renal proximal tubule being responsible for approximately 90% of glucose re-uptake in the kidney. Inhibition of SGLT2 is an exciting new pharmacological approach for the reduction of blood glucose in type 2 diabetic patients via inhibition of tubular glucose reabsorption. In addition to lowering glucose, this group of drugs has shown significant cardiovascular and renal protective effects. Conclusion: This review aims to outline the current state of preclinical research and clinical trials for different SGLT2 inhibitors and outline some of the proposed mechanisms of action, including possible effects on sympathetic nerve activity, which may contribute to the unexpected beneficial cardiovascular and reno-protective effects of this class of compounds.

Original languageEnglish
Pages (from-to)349-356
Number of pages8
JournalCurrent Diabetes Reviews
Volume15
Issue number5
DOIs
Publication statusPublished - 1 Jan 2019

Keywords

  • Cardiovascular and renoprotection
  • Diabetic micro-and macrovascular complications
  • Reactive oxygen species
  • SGLT-2
  • Sympathetic nerves
  • Therapeutics

Cite this

@article{890d1c46af1b4d63bc188a97c798b504,
title = "SGLT-2 Inhibition: Novel therapeutics for reno-and cardioprotection in diabetes mellitus",
abstract = "Background: The sodium glucose co-transporter 2 (SGLT2) is primarily located within S1 of the renal proximal tubule being responsible for approximately 90{\%} of glucose re-uptake in the kidney. Inhibition of SGLT2 is an exciting new pharmacological approach for the reduction of blood glucose in type 2 diabetic patients via inhibition of tubular glucose reabsorption. In addition to lowering glucose, this group of drugs has shown significant cardiovascular and renal protective effects. Conclusion: This review aims to outline the current state of preclinical research and clinical trials for different SGLT2 inhibitors and outline some of the proposed mechanisms of action, including possible effects on sympathetic nerve activity, which may contribute to the unexpected beneficial cardiovascular and reno-protective effects of this class of compounds.",
keywords = "Cardiovascular and renoprotection, Diabetic micro-and macrovascular complications, Reactive oxygen species, SGLT-2, Sympathetic nerves, Therapeutics",
author = "Angus Gill and Gray, {Stephen P.} and Jandeleit-Dahm, {Karin A.} and Watson, {Anna M.D.}",
year = "2019",
month = "1",
day = "1",
doi = "10.2174/1573399814666180417121246",
language = "English",
volume = "15",
pages = "349--356",
journal = "Current Diabetes Reviews",
issn = "1573-3998",
publisher = "Bentham Science Publishers",
number = "5",

}

SGLT-2 Inhibition : Novel therapeutics for reno-and cardioprotection in diabetes mellitus. / Gill, Angus; Gray, Stephen P.; Jandeleit-Dahm, Karin A.; Watson, Anna M.D.

In: Current Diabetes Reviews, Vol. 15, No. 5, 01.01.2019, p. 349-356.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - SGLT-2 Inhibition

T2 - Novel therapeutics for reno-and cardioprotection in diabetes mellitus

AU - Gill, Angus

AU - Gray, Stephen P.

AU - Jandeleit-Dahm, Karin A.

AU - Watson, Anna M.D.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: The sodium glucose co-transporter 2 (SGLT2) is primarily located within S1 of the renal proximal tubule being responsible for approximately 90% of glucose re-uptake in the kidney. Inhibition of SGLT2 is an exciting new pharmacological approach for the reduction of blood glucose in type 2 diabetic patients via inhibition of tubular glucose reabsorption. In addition to lowering glucose, this group of drugs has shown significant cardiovascular and renal protective effects. Conclusion: This review aims to outline the current state of preclinical research and clinical trials for different SGLT2 inhibitors and outline some of the proposed mechanisms of action, including possible effects on sympathetic nerve activity, which may contribute to the unexpected beneficial cardiovascular and reno-protective effects of this class of compounds.

AB - Background: The sodium glucose co-transporter 2 (SGLT2) is primarily located within S1 of the renal proximal tubule being responsible for approximately 90% of glucose re-uptake in the kidney. Inhibition of SGLT2 is an exciting new pharmacological approach for the reduction of blood glucose in type 2 diabetic patients via inhibition of tubular glucose reabsorption. In addition to lowering glucose, this group of drugs has shown significant cardiovascular and renal protective effects. Conclusion: This review aims to outline the current state of preclinical research and clinical trials for different SGLT2 inhibitors and outline some of the proposed mechanisms of action, including possible effects on sympathetic nerve activity, which may contribute to the unexpected beneficial cardiovascular and reno-protective effects of this class of compounds.

KW - Cardiovascular and renoprotection

KW - Diabetic micro-and macrovascular complications

KW - Reactive oxygen species

KW - SGLT-2

KW - Sympathetic nerves

KW - Therapeutics

UR - http://www.scopus.com/inward/record.url?scp=85051713865&partnerID=8YFLogxK

U2 - 10.2174/1573399814666180417121246

DO - 10.2174/1573399814666180417121246

M3 - Review Article

C2 - 29663893

AN - SCOPUS:85051713865

VL - 15

SP - 349

EP - 356

JO - Current Diabetes Reviews

JF - Current Diabetes Reviews

SN - 1573-3998

IS - 5

ER -